Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … WebArms in the two indications will consist of two cohorts each and will investigate IPH4102 in KIR3DL2 expressing and non-expressing patients. The trial’s primary endpoint is objective response rate and key secondary measures include treatment emergent adverse events, quality of life, overall response rate, progression-free survival, and overall survival.
TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
Web29 nov. 2024 · Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood involvement and expression o… Web3 dec. 2024 · innate pharma announces updated results that support advancement of iph4102 in refractory sÉzary syndrome at the american society of hematology 2024 annual meeting differentiating... march 26, 2024 hii family health center cvs
Lacutamab - TELLOMAK Study Cutaneous Lymphoma Foundation
Web30 okt. 2014 · IPH4102 was effective in autologous killing assays in which it induces NK cell–based lysis of autologous Sézary cells, demonstrating both the functional integrity of … Web7 jun. 2024 · IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody that depletes KIR3DL2-expressing cells through antibody-dependent cell-cytotoxicity and … Web• Initiation of IPH4102 , an international, openTELLOMAK -label, multicohort Phase II - study evaluating the efficacy and safety of IPH4102 in patient populations larger expressing KIR3DL2, including peripheral T cell lymphoma (PTCL). TELLOMAK is planned to recruit up to 250 patients, with IPH4102 evaluated as a single agent in hii family health